{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:53:31Z","timestamp":1760241211428,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,12,29]],"date-time":"2019-12-29T00:00:00Z","timestamp":1577577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins thrombosis; treatment and prevention of pulmonary embolism. Dabigatran is a relatively new drug, and as a result, its interactions with other medications and their significance are not fully known. A 72 years old male, having a medical history of heart and renal failure, was hospitalized for pneumonia treatment. The patient was taking several drugs, including dabigatran 150 mg twice daily and ranolazine 750 mg twice daily. His creatinine clearance was 45.22 mL\/min, International Normalized Ratio (INR)\u20147.03. Dabigatran was discontinued. After 9 days, INR decreased to 1.33, and after 6 days, creatinine clearance increased to 64.39 mL\/min. The patient was taking an adequate dosage of dabigatran, thus dabigatran was thought to be overdosed due to its interaction with ranolazine because dabigatran is a p-glycoprotein substrate, whereas ranolazine is the inhibitor of this transporter. Dabigatran and ranolazine should be used with caution in patients with renal failure. It is recommended to use smaller doses of both medications and observe coagulation parameters if needed.<\/jats:p>","DOI":"10.3390\/medicina56010013","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T05:49:41Z","timestamp":1577684981000},"page":"13","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure"],"prefix":"10.3390","volume":"56","author":[{"given":"Gintautas","family":"Gumbrevi\u010dius","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Institute of Physiology and Pharmacology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania"},{"name":"Department of Internal Medicine, Kaunas Clinical Hospital, 44127 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-6392","authenticated-orcid":false,"given":"Gyt\u0117","family":"Damulevi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania"},{"name":"Department of Geriatrics, Kaunas Clinical Hospital, 44127 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaidotas","family":"Galaun\u0117","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Institute of Physiology and Pharmacology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milda","family":"Gumbrevi\u010di\u016bt\u0117","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaunas Clinical Hospital, 44127 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,29]]},"reference":[{"key":"ref_1","unstructured":"European Medicines Agency (2019, November 18). Pradaxa. Summary of Products Characteristics. Available online: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190513144929\/anx_144929_en.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Stuart","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"European Medicines Agency (2019, November 18). Ranexa. Summary of Products Characteristics. Available online: http:\/\/ec.europa.eu\/health\/documents\/community-register\/2018\/20181122142605\/anx_142605_en.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1742-1241.2009.02286.x","article-title":"Drug and dietary interactions of the new and emerging oral anticoagulants","volume":"64","author":"Walenga","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory Measurement of the Anticoagulant Activity of the Non\u2013Vitamin K Oral Anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"131395","DOI":"10.1155\/2013\/131395","article-title":"Case report. Coagulopathy and Extremely Elevated PT\/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease","volume":"2013","author":"Kim","year":"2013","journal-title":"Case Rep. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40119-013-0016-1","article-title":"Dabigatran Excess: Case Report and Review of the Literature","volume":"2","author":"Sarma","year":"2013","journal-title":"Cardiol. Ther."},{"key":"ref_10","first-page":"6","article-title":"Excess of Dabigatran Associated with Raised INR, PT, APTT in an Elderly Patient with Renal Impairment","volume":"2","author":"Liyanage","year":"2018","journal-title":"Int. J. Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2011.314","article-title":"The use of dabigatran in elderly patients","volume":"171","author":"Legrand","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","article-title":"The P-Glycoprotein Transport System and Cardiovascular Drugs","volume":"61","author":"Jeffrey","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","first-page":"1","article-title":"Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris","volume":"5","author":"Aldakkak","year":"2013","journal-title":"Clin. Med. Insights Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical Pharmacokinetics of Ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","unstructured":"(2019, December 02). Drug Interaction Report. Available online: https:\/\/www.drugs.com\/interactions-check.php?drug_list=3266-0,1993-1284."},{"key":"ref_16","unstructured":"(2019, December 02). LVB Remote DB Access Service. Available online: https:\/\/www-micromedexsolutions-com.ezproxy.dbazes.lsmuni.lt\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowDrugInteractionsResults."},{"key":"ref_17","unstructured":"(2019, December 02). Drug Interaction Checker. Available online: https:\/\/www.rxlist.com\/drug-interaction-checker.htm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/1\/13\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:46:32Z","timestamp":1760190392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/1\/13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,29]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["medicina56010013"],"URL":"https:\/\/doi.org\/10.3390\/medicina56010013","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2019,12,29]]}}}